FDMT - Company ID 0001650648
The table below shows 4D Molecular Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $85.21M | $37.00K | $20.72M | $3.13M | $18.04M | $13.61M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A | $49.06M |
4D Molecular Therapeutics, Inc. reported annual revenue of $85.21M for fiscal year 2025. That is up 230194.6% from $37.00K in fiscal 2024. Over the 7 fiscal years shown, annual revenue grew from $6.99M (FY 2019) to $85.21M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $46.58M |
| $36.49M |
| $32.91M |
| $28.01M |
| $17.24M |
| Operating income | -$159.55M | -$187.84M | -$112.87M | -$110.03M | -$71.33M | -$56.66M |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$140.11M | -$160.87M | -$100.84M | -$107.49M | -$71.32M | -$56.69M |
| EPS (diluted) | -$2.42 | -$2.98 | -$2.58 | -$3.32 | -$2.57 | - |